

# Christophe Hirtz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10645474/publications.pdf>

Version: 2024-02-01

67  
papers

1,790  
citations

304743

22  
h-index

315739

38  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3218  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 860-869.	10.2	140
2	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 26.	6.2	138
3	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1033-1043.	2.6	104
4	Current and future use of "dried blood spot" analyses in clinical chemistry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1897-1909.	2.3	102
5	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. <i>Journal of Proteome Research</i> , 2016, 15, 667-676.	3.7	91
6	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. <i>Neurobiology of Aging</i> , 2017, 53, 59-66.	3.1	76
7	MS characterization of multiple forms of alpha-amylase in human saliva. <i>Proteomics</i> , 2005, 5, 4597-4607.	2.2	70
8	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
9	Proteins and proteolysis in pre-term and term human milk and possible implications for infant formulae. <i>International Dairy Journal</i> , 2010, 20, 715-723.	3.0	56
10	Use of Reducing/Nonreducing Two-Dimensional Electrophoresis for the Study of Disulfide-Mediated Interactions between Proteins in Raw and Heated Bovine Milk. <i>Journal of Agricultural and Food Chemistry</i> , 2009, 57, 5948-5955.	5.2	54
11	Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 919-35.	2.3	47
12	Alzheimer's Disease: Advances in Drug Development. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 3-13.	2.6	45
13	SILK studies " capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2019, 15, 419-427.	10.1	37
14	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. <i>Scientific Reports</i> , 2016, 6, 25162.	3.3	36
15	Peripheral Blood and Salivary Biomarkers of Blood " Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. <i>Frontiers in Neurology</i> , 2020, 11, 577312.	2.4	36
16	Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. <i>Frontiers in Neuroscience</i> , 2015, 9, 302.	2.8	34
17	Cerebrospinal fluid A beta 1 " 40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	6.2	33
18	Quantitative detection of amyloid- $\beta$ peptides by mass spectrometry: state of the art and clinical applications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1483-93.	2.3	30

#	ARTICLE	IF	CITATIONS
19	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	1.9	30
20	Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?. <i>Clinica Chimica Acta</i> , 2017, 467, 51-58.	1.1	29
21	Association between serum hepcidin level and restless legs syndrome. <i>Movement Disorders</i> , 2018, 33, 618-627.	3.9	25
22	Detection of amyloid beta peptides in body fluids for the diagnosis of Alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 99-113.	6.1	24
23	Proteomic Studies of Saliva: A Proposal for a Standardized Handling of Clinical Samples. <i>Clinical Proteomics</i> , 2007, 3, 13-21.	2.1	23
24	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 759-764.	2.6	23
25	Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. <i>Bioanalysis</i> , 2016, 8, 43-53.	1.5	22
26	Hepcidin and ferritin levels in restless legs syndrome: a case-control study. <i>Scientific Reports</i> , 2020, 10, 11914.	3.3	21
27	Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Top-Down Proteomics: A Pilot Study. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 477.	2.9	20
28	The prognostic value of the $\tau$ protein serum level in metastatic breast cancer patients and its correlation with brain metastases. <i>BMC Cancer</i> , 2019, 19, 110.	2.6	20
29	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. <i>EuPA Open Proteomics</i> , 2014, 3, 60-67.	2.5	19
30	Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. <i>Clinica Chimica Acta</i> , 2016, 454, 33-38.	1.1	19
31	Clinical perspectives of dried blood spot protein quantification using mass spectrometry methods. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 173-184.	6.1	19
32	Salivary protein profiling in type I diabetes using two-dimensional electrophoresis and mass spectrometry. <i>Clinical Proteomics</i> , 2006, 2, 117-127.	2.1	18
33	Towards a routine application of Top-Down approaches for label-free discovery workflows. <i>Journal of Proteomics</i> , 2018, 175, 12-26.	2.4	17
34	Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study. <i>BMJ Open</i> , 2019, 9, e025129.	1.9	17
35	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1291-1295.	2.6	16
36	Impurity determination for hepcidin by liquid chromatography-high resolution and ion mobility mass spectrometry for the value assignment of candidate primary calibrators. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 2559-2567.	3.7	16

#	ARTICLE	IF	CITATIONS
37	Comparison of HbA1c detection in whole blood and dried blood spots using an automated ion-exchange HPLC system. <i>Bioanalysis</i> , 2017, 9, 427-434.	1.5	14
38	Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 1-18.	6.1	14
39	Quantification of hepcidin-25 in human cerebrospinal fluid using LC-MS/MS. <i>Bioanalysis</i> , 2017, 9, 337-347.	1.5	12
40	Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples. <i>Bioanalysis</i> , 2018, 10, 35-45.	1.5	12
41	Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. <i>Data in Brief</i> , 2018, 18, 1013-1021.	1.0	12
42	What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. <i>Bioanalysis</i> , 2018, 10, 723-735.	1.5	12
43	Stable Isotope Labeling by Amino acid in Vivo (SILAV): a new method to explore protein metabolism. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 1917-1925.	1.5	10
44	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2017, 36, 391-396.	1.4	9
45	Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 346-358.	6.1	9
46	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 903-911.	2.6	9
47	Gravitational Transitions Increase Posterior Cerebral Perfusion and Systemic Oxidative-nitrosative Stress: Implications for Neurovascular Unit Integrity. <i>Neuroscience</i> , 2020, 441, 142-160.	2.3	9
48	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid $\beta$ peptides in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 649-55.	2.3	8
49	Biochemical markers of time since death in cerebrospinal fluid: A first step towards Forensics. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 274-286.	6.1	8
50	Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1605-1618.	5.1	8
51	From Clinical Proteomics to Clinical Chemistry Proteomics: considerations using quantitative mass-spectrometry as a model approach. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 235-42.	2.3	7
52	Variation of human salivary alpha-amylase proteoforms in three stimulation models. <i>Clinical Oral Investigations</i> , 2020, 24, 475-486.	3.0	7
53	Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?. <i>International Journal of Legal Medicine</i> , 2021, 135, 2081-2089.	2.2	7
54	Concussion history in rugby union players is associated with depressed cerebrovascular reactivity and cognition. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2021, 31, 2291-2299.	2.9	7

#	ARTICLE	IF	CITATIONS
55	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	2.8	7
56	Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1086, 110-117.	2.3	6
57	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. <i>Analytical Chemistry</i> , 2019, 91, 15500-15508.	6.5	6
58	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. <i>Bioanalysis</i> , 2021, 13, 1029-1035.	1.5	6
59	Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry. <i>Bioanalysis</i> , 2018, 10, 1383-1399.	1.5	5
60	Changes Occurring on the Activity of Salivary Alpha-Amylase Proteoforms in Two Naturalistic Situations Using a Spectrophotometric Assay. <i>Biology</i> , 2021, 10, 227.	2.8	5
61	Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infection. <i>Immunologic Research</i> , 2021, 69, 255-263.	2.9	5
62	Efficient extraction of intact HSA-A $\beta$ <sup>2</sup> peptide complexes from sera: Toward albuminome biomarker identification. <i>Talanta</i> , 2020, 216, 121002.	5.5	4
63	Soluble Intercellular Adhesion Molecule- (sICAM-) 1, Thrombospondin-1, and Vinculin for the Identification of Septic Shock Patients Suffering from an Invasive Fungal Infection. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	3.0	2
64	What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis?. <i>Bioanalysis</i> , 2015, 7, 2849-2851.	1.5	1
65	Characterizing Deep White Matter Hyperintensities in Patients with Symptomatic Isolated Cortical Superficial Siderosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 465-469.	1.6	1
66	Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 173-190.	0.7	0
67	Intact Protein Analysis by LC-MS for Characterizing Biomarkers in Cerebrospinal Fluid. <i>Methods in Molecular Biology</i> , 2019, 1959, 163-172.	0.9	0